"Colistin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
| Descriptor ID |
D003091
|
| MeSH Number(s) |
D04.345.566.780.110 D10.477.750.110 D12.644.050.600.110 D12.644.641.780.110 D12.776.543.695.054.600.110
|
| Concept/Terms |
Colistin- Colistin
- Colisticin
- Polymyxin E
- Colimycin
|
Below are MeSH descriptors whose meaning is more general than "Colistin".
Below are MeSH descriptors whose meaning is more specific than "Colistin".
This graph shows the total number of publications written about "Colistin" by people in this website by year, and whether "Colistin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Colistin" by people in Profiles.
-
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39.
-
Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.
-
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
-
Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.